Last reviewed · How we verify
NOAC: Apixaban
At a glance
| Generic name | NOAC: Apixaban |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis (PHASE1)
- Monitoring of NOAC Therapy: Standardizing Reference Intervals
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- DOAC - Dosing Options in AntiCoagulation Prophylaxis (PHASE3)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOAC: Apixaban CI brief — competitive landscape report
- NOAC: Apixaban updates RSS · CI watch RSS
- Bayer portfolio CI